Roche Holding AG GS buy melinda
Start price
28.06.16
/
50%
€226.81
Target price
28.12.16
€260.00
Performance (%)
-4.01%
End price
28.12.16
€217.72
Summary
This prediction ended on 28.12.16 with a price of €217.72. With a performance of -4.01%, the BUY prediction by melinda finished with a loss. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Roche Holding AG GS | - | - | - | - |
| iShares Core DAX® | 2.594% | -1.158% | 14.782% | 16.813% |
| iShares Nasdaq 100 | 3.553% | -1.727% | 43.265% | 44.227% |
| iShares Nikkei 225® | 0.687% | -8.354% | 18.454% | 1.361% |
| iShares S&P 500 | 2.209% | -0.942% | 31.361% | 42.812% |
According to melinda what are the pros and cons of Roche Holding AG GS for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Roche Holding AG NV diskutieren
folgen
2016.06.28 | 9.36
Roche gab am Dienstag bekannt, dass die Europäische Arzneimittel-Agentur (EMA) zugestimmt hatte seinen Antrag auf Registrierung auf der Ocrevus (Ocrelizumab) bei der Behandlung von Multipler Sklerose in seiner zyklischen und progressive Formen zu betrachten.
(Laufzeit überschritten)
Stopped prediction by melinda for Roche Holding AG GS
Roche Holding AG GS
Start price
Target price
Perf. (%)
€240.20
23.05.19
23.05.19
€300.00
04.11.21
04.11.21
2.44%
05.11.21
05.11.21
Could be worthwhile Investment >10% per year
Roche Holding AG GS
Start price
Target price
Perf. (%)
€200.10
21.01.18
21.01.18
€244.00
23.07.18
23.07.18
3.85%
23.07.18
23.07.18
Could be worthwhile Investment >10% per year
Roche Holding AG GS
Start price
Target price
Perf. (%)
€234.75
23.06.17
23.06.17
€272.00
25.12.17
25.12.17
-10.54%
25.12.17
25.12.17
Could be worthwhile Investment >10% per year
Roche Holding AG GS
Start price
Target price
Perf. (%)
€234.75
23.06.17
23.06.17
€272.00
25.12.17
25.12.17
-10.54%
25.12.17
25.12.17
Could be worthwhile Investment >10% per year